Skip to main content
Download PDF

Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial

BMC Complementary Medicine and Therapies volume 24, Article number: 109 (2024) Cite this article

Abstract

Aim

We conducted a randomized placebo-controlled trial to assess the efficacy of Spirulina (SP) supplementation on disease activity, health-related quality of life, antioxidant status, and serum pentraxin 3 (PTX-3) levels in patients with ulcerative colitis (UC).

Methods

Eighty patients with UC were randomly assigned to consume either 1 g/day (two 500 mg capsules/day) of SP (n = 40) or control (n = 40) for 8 weeks. Dietary intakes, physical activity, disease activity, health-related quality of life, antioxidant status, erythrocyte sedimentation rate (ESR), and serum PTX-3 levels were assessed and compared between groups at baseline and post-intervention.

Results

Seventy-three patients (91.3%) completed the trial. We observed increases in serum total antioxidant capacity levels in the SP supplementation group compared to the control group after 8 weeks of intervention (p ≤ 0.001). A within-group comparison indicated a trend towards a higher health-related quality of life score after 8 weeks of taking two different supplements, SP (p < 0.001) and PL (p = 0.012), respectively. However, there were no significant changes in participant’s disease activity score in response to SP administration (p > 0.05). Similarly, changes in ESR and PTX-3 levels were comparable between groups post-intervention (p > 0.05).

Conclusions

SP improved antioxidant capacity status and health-related quality of life in patients with UC. Our findings suggest that SP supplementation may be effective as an adjuvant treatment for managing patients with UC. Larger trials with longer interventions periods are required to confirm our findings.

Peer Review reports

Introduction

Ulcerative colitis (UC) is a prevalent type of Inflammatory Bowel Disease (IBD) characterized by chronic inflammation, ulcers in the distal part of the intestine, and clinically recurrent phases of aggravation and remission [1]. Although the etiology of UC is poorly elucidated, growing evidence has revealed that interactions between several components, including genetic variations in the intestinal microbiome, immune responses, and environmental factors, may play a role [2,3,4,5], UC represents an underlying cause of various other disorders, including intermittent diarrhea and constipation, cramping, abdominal, rectal, or joint pain, bleeding, and/or anemia [6,7,8]. Thus, identifying and treating pathophysiological factors can play an indispensable role in reducing UC-related complications.

Inflammatory markers, which involved the pathophysiology of UC, have received attention as a method for indirect assessment of UC and a potential therapeutic target for this condition [9]. To that end, acute phase inflammatory markers such as C reactive protein (CRP) or the erythrocyte sedimentation rate (ESR) in plasma are measured for this purpose [9, 10]. Emerging evidence also indicated that serum pentraxin-3 (PTX-3) is an important inflammatory marker for IBD [11, 12]. Short pentraxins (e.g., CRP, serum amyloid P) are produced by hepatocytes [13]; in contrast, PTX-3 as a long member of the pentraxin superfamily is produced by innate immunity cells in response to inflammatory cytokine and tissue damage [11, 12]. The PTX-3 is released mainly from neutrophils in inflamed colon tissue in UC patients, especially in crypt abscess injuries [14, 15]. Therefore, PTX-3 is an independent biomarker of disease activity produced at the site of inflammation, which may be helpful as a rapid disease activity biomarker to detect and treat primary local inflammation induced by epithelial damage and crypt abscess in patients with UC. Although immunosuppressants and anti-inflammatory medications are commonly used for patients with UC [16], these pharmacological treatments induce several adverse effects, including raised risk of infection, low bone mineral density, liver disease, tremor, eye disorders, gastrointestinal disease, pancreatitis, and antigen-antibody response [17, 18]. Thus, applying a comparably safer adjuvant treatment with fewer side effects and lower toxicities may be more favorable in UC management.

Over recent decades, evidence has supported the benefits of select herbal therapies on UC due to their bioactive compounds’ healing or antioxidant characteristics. These therapies are generally considered safe for managing UC-related complications [19,20,21,22,23,24]. Namely, Spirulina (SP; Arthrospira platensis) which is a biomass of cyanobacteria (blue-green algae) [25, 26]. This alga, predominantly classified as a phytomedicine, has been widely consumed as a dietary supplement or a whole food. It is considered a good source of essential nutrients, including phytochemicals (carotenoids, phycocyanins), minerals (calcium, iron), amino acids, essential fatty acids, vitamins (vitamin B12, provitamin A), and fiber [27,28,29]. SP has anti-inflammatory, antioxidant, liver-protecting, antiviral, and microbiome-regulating properties and has been suggested as an effective adjuvant therapy for managing many disorders [27, 28, 30, 31]. SP’s antioxidant and anti-inflammatory effects are specifically remarkable in the management of chronic diseases, including IBD [32, 33]. Previous studies documented that SP supplementation decreases inflammatory cytokines, such as tumor necrosis factor (TNF)-α [34], interleukin-6 (IL-6) [35], CRP [36], ESR [37], and PTX-3 [38]. In addition, several studies reported that SP administration significantly affects oxidant and antioxidant parameters. For instance, SP supplementation has been shown to reduce malondialdehyde (MDA) levels [39] and increase total antioxidant capacity (TAC), superoxide dismutase (SOD), and glutathione peroxidase (GPx) levels [35, 40,41,42]. However, these studies mainly focused on the effect of SP on inflammatory and antioxidant factors per se, and the effect of this microalgae compound has been poorly elucidated on clinical outcome measures of patients with inflammatory conditions, including those with chronic colitis. Therefore, the purpose of this investigation was to evaluate the effects of SP supplementation on disease activity, health-related quality of life, serum antioxidant status, and PTX-3 levels in patients with UC.

Materials and methods

Participants’ characteristics

Eighty patients with UC (age: 38.64 ± 11.30 years, height: 166 ± 8.57 cm, and BMI: 25.81 ± 4.96 kg/m2) referred to the Imam Reza Hospital (Kermanshah, Iran) were enrolled in the study. Participants were included if they (1) were clinically diagnosed with UC using a colonoscopy exam, clinical records, and pathology assessment; (2) were between 18 and 65 years of age; and (3) exhibited symptoms of active mild to moderate UC disease (5 ≤ or ≤ 12 scores based on the Simple Clinical Colitis Activity Index [SCCAI]) [43]. Patients were excluded if they (1) had good or severe ulcerative colitis (SCCAI scores of < 5 or > 12); (2) were pregnant or breastfeeding; (3) consumed antidepressants, anxiety medications, antioxidants, omega-3, or other supplements in the past 3 months; (4) smoked or consumed alcohol; (5) had heart, liver, kidney, cancer, thyroid, parathyroid, or other gastrointestinal conditions; or (6) had poor compliance to SR supplementation protocol (consumed < 90% of their supplements during the intervention period).

Experimental protocol

This study was a double-blind and placebo-controlled randomized clinical trial. Prior to baseline measurements, participants were fully familiarized with all experimental procedures. Patients with active mild to moderate UC were randomly allocated to one of two groups: a SP supplementation (n = 40) or control (n = 40) utilizing simple randomization via a random number table. Prior to and following our eight-week study duration, measures of anthropometry, dietary intake, disease activity, health-related quality of life, serum antioxidant status, and PTX-3 levels were made. All patients were instructed to continue their usual lifestyles, including physical activity, dietary intake, and medication regimen throughout the study period. Compliance with the assigned intervention was evaluated through weekly phone calls and monitoring the number of supplement packages used. Patients, laboratory staff, researchers, and participants were blinded to the supplement allocation until the end of the trial period.

Randomization and blinding

The study employed a simple randomization method, facilitated by a random number table. Throughout the duration of the trial, the participants, laboratory personnel, and researchers were blinded to treatment assignment. At no time during the intervention were the investigators and/or participants aware of which treatment was being provided to study participants.

Spirulina supplementation

The SP group was supplemented with a 500 mg capsule of SP twice per day, before lunch and dinner. The control group received two placebo capsules containing 500 mg corn starch without chlorophyll during the same time periods. The placebo capsules had similar color, size, and shape compared to SP capsules. The selected dose and time of ingestion were based on prior investigations [44,45,46,47,48]. The SP powder was produced by the Javane Sabz Company, Shiraz, Iran. The chemical composition of Spirulina and placebo per 100 g is reported in Table 1. All chemical analytical procedures were completed in the Beh-Azma laboratory (Iran) in compliance with the assessment methods recommended by the Association of Analytical Communities. Both the SP and placebo capsules were prepared by researchers under sterile conditions, including the measurement of the weight and quality.

Table 1 Chemical composition of Spirulina and placebo per 1 g of product weight (capsule content)
Full size table

Outcome assessments

Height was evaluated via a nonelastic wall-mounted stadiometer, measured to the nearest 0.5 cm. Body mass was assessed with participants dressed in light clothes using a digital scale to the nearest 0.1 kg. Body mass index (BMI) was calculated using a formula: Weight (kg)/ the square of the body height (m2).

To assess the dietary intake of each patient, food diaries were collected for 3 days, including two weekdays and one weekend day. Nutrient intakes were assessed using the Nutritionist IV software (First Databank, San Bruno, CA) modified for Iranian foods. Physical activity levels were evaluated via a short form of the International Physical Activity Questionnaire (IPAQ) [49].

Patients’ disease activity was assessed using the SCCAI questionnaire score, which correlates closely to biochemical parameters of UC, and is valid and reliable for evaluating patients with this condition [50]. This questionnaire has various parts with a total score ranging from zero to 19. Higher scores indicate higher severity of UC symptoms during the past week. Moreover, the Short IBD Questionnaire (SIBDQ) score was used to assess health-related quality of life (HRQoL) in IBD patients. The validity and reliability of SIBDQ were first confirmed (r = 0.83) by Jowett et al. for patients with UC [51] and subsequently in an Iranian cohort [52]. Each question of SIBDQ has seven items and covers scores of 1 to 7.

Blood samples were obtained between 8:00, and 10:00 am after an overnight fast (12 hours) at baseline and post-intervention. The erythrocyte sedimentation rate (ESR) was determined by the Westergren assay. The blood samples were centrifuged (3500 rpm), and the aliquots were stored at − 80 °C before further analysis. Total antioxidant capacity (TAC) was assessed according to the ferric reducing antioxidant power (FRAP) method using a commercial kit (Kiazist, Iran). MDA level was evaluated based on the thiobarbituric acid reactive substance (TBARS) using a commercial kit (Kiazist, Iran). Superoxide dismutase (SOD) concentration was also measured according to the ability of Mn-SOD to inhibit the conversion of resazurin to resorufin accompanied by reducing superoxide radicals produced by the xanthine/xanthine oxidase system using a commercial kit (Kiazist, Iran). All intra- and inter-assay coefficients of variation were less than 10%. Finally, the serum PTX-3 levels were evaluated using the enzyme-linked immunosorbent assay (ELISA) with an intra- and inter-assay coefficient of variability (CV) less than 5% by a Human PTX-3 Test kit (Crystal, China) based on the manufacturer’s guideline.

Sample size calculation

We conducted an a priori calculation of sample size using the G*Power analysis software [53], accounting for a Type I error rate of 5% and a statistical power of 80%. A minimum detectable effect size (i.e., Δ of clinical response) of 0.3 was considered clinically plausible using data from previous clinical trials in patients with UC [54, 55]. Our calculated sample size was 33 participants in each group. Ultimately, 40 patients in each experimental arm were estimated to be sufficient after considering a 20% dropout rate.

Safety assessment

Adverse events that may or may not be associated with the study therapies, including abnormal gastrointestinal reactions, cardiovascular events, allergic reactions, and other medical conditions were recorded.

Statistical methods

We presented continuous variables as mean ± standard deviation (SD) and expressed categorical variables as frequencies (percentage). The normality of data distribution was assessed using the Shapiro–Wilk test and Q–Q plot. For normally distributed variables, we used an independent sample t-test for comparison, and for non-normally distributed variables, the Mann–Whitney U test was employed. Categorical variables were analyzed using the chi-square test. The mean of markers between the SP and PL groups was compared using an independent t-test, and changes over time were evaluated utilizing a paired t-test. To examine the impact of the group on the markers in the post-test, controlling for the effects of baselines, we employed analysis of covariance (ANCOVA). If the homogeneity of variance was not met, we estimated the parameter with robust standard errors. The analyses were conducted using SPSS (version 26, Armonk, NY, USA) and STATA version 17 (Stata Corp LLC, TX, USA), and p-values less than 0.05 were considered statistically significant.

Results

Between May 2020 and January 2021, we screened 426 both female and male patients with UC. Of these, 346 were excluded for not meeting the exclusion criteria (n = 259) and for declining to participate (n = 87). Consequently, 80 participants with mild or moderate degrees of UC disease were enrolled in the current study and randomly assigned to the SP and control groups. Three patients withdrew before completing the study for personal reasons and four due to changes in their medication use (Fig. 1). Data are presented for the 73 patients (n = 36 and n = 37 in the SP and control groups, respectively) that completed our eight-week intervention. Participants’ compliance with their intervention was > 90% in both groups.

Fig. 1
figure 1

Participants’ flow diagram

Full size image

Participant’s characteristics

The mean age of participants in SP and PL group was 37.80 and 39.50 years which was homogenate by the group. Results showed that the difference of markers between SP and PL was not significant in pretest (baseline) (Table 2). However, the mean of markers Calcium (p = 0.007, ESCohen ′ s d = 0.64), Magnesium (p = 0.040, ESCohen ′ s d = 0.49) and B9 (p = 0.012, ESCohen ′ s d = 0.60) in post-test were significantly different by group (Table 3). In addition, there was a significant mean difference in marker (post – pre) (SIBDQ score) in both groups (SP: p = < 0.001, ESCohen ′ s d = 0.87, PL: p = 0.012, ESCohen ′ s d =0.43). (Table 4).

Table 2 Participants’ baseline characteristics
Full size table
Table 3 Nutrients intake, physical activity, and anthropometrics at pre and post intervention
Full size table
Table 4 Descriptive statistics of variables by group and time-point
Full size table

In the next step, the ANCOVA was used to evaluate the impact of the group on markers measured in post-test adjusting the baselines. Accordingly, the post means of protein (β = 1.22, 95% CI (0.87, 1.60), ESPartial Eta Squared = 0.41) and Iron (β = 1.16, 95% CI (0.56, 1.76), ESPartial Eta Squared =0.17) were significantly higher in SP compared to PL. However, the waist-to-height ratio (β = 1.00, 95% CI (0.95,1.05), ESPartial Eta Squared = 0.95), BMI (β = 1.00, 95% CI (0.99, 1.04), ESPartial Eta Squared = 0.99), physical activity (β = 1.00, 95% CI (0.99,1.01), ESPartial Eta Squared = 0.99), energy (β = 1.00, 95% CI (0.88,1.13), ESPartial Eta Squared = 0.78), vitamin B1 (β = 1.00, 95% CI (0.96,1.04), ESPartial Eta Squared = 0.97), Lycopene (β = 1.00, 95% CI (0.97, 1.03), ESPartial Eta Squared = 0.98), had equal mean value in SP and PL group. (Table 5).

Table 5 The impact of SP vs. PL on the markers
Full size table

Dietary intake and physical activity levels

As Table 3 shows, most nutrients remained unchanged over time except for calcium, magnesium, and vitamin B9 in SP group. In addition, the independent t-test (Table 3) indicated that the levels of all the nutrients were significantly different in the SP compared to the PL group, with the exception of linoleic acid, oleic acid, docosahexaenoic acid, α-Tocopherol, vitamin B6, vitamin D, fiber, galactose, and maltose and lutein (p > 0.05). Physical activity (Table 3) remained unchanged over time in both groups (p > 0.05).

Health-related quality of life and SCCAI score

The effect of SP administration on SIQBD and SCCAI scores in patients with UC is reported in Fig. 2. A within-group comparison indicated a trend towards a higher SIQBD score after 8 weeks of taking two different supplements, SP and PL, respectively (p < 0.001, ESCohen ′ s d = 0.87 and p = 0.012, ESCohen ′ s d = 0.43). However, there were no significant changes in participants SCCAI score in response to SP administration (p > 0.05).

Fig. 2
figure 2

The effects of spirulina supplementation on SIQBD and SCCAI scores in patients with ulcerative colitis

Full size image

Antioxidant status and inflammatory markers

The effect of SP supplementation on antioxidant status and inflammatory parameters in patients with UC is reported in Fig. 3. The within-group comparison revealed a significant decrease in serum MDA after 8 weeks of SP supplementation (p = 0.01, ESCohen ′ s d = 0.45), but their TAC, SOD, ESR, and PTX-3 remained unchanged post-intervention (p > 0.05). In contrast, the within-group comparison revealed no significant changes in serum antioxidant status and inflammatory parameters in the control group (p > 0.05). Our ANCOVA analyses revealed a significant increase in serum TAC after 8 weeks of intervention in the SP supplementation group vs. the control group (β = 0.83, 95% CI (0.60,1.10), ESPartial Eta Squared = 0.37). Moreover, no significant differences were observed in changes of MDA, SOD, ESR, and PTX-3 levels between groups from baseline to post-intervention (p > 0.05).

Fig. 3
figure 3

The effects of spirulina supplementation on antioxidant status and inflammatory markers

Full size image

Adverse effects

Overall, SP supplementation was well tolerated by patients and did not yield any severe adverse effects (e.g., allergic reactions). However, 5 out of 36 patients (13.8%) reported mild adverse effects, evidenced by mild bloating early in the trial. All bloating events were resolved later during the intervention.

Discussion

The present trial evaluated the efficacy of SP supplementation on disease activity, health-related quality of life, serum antioxidant status, and PTX-3 levels in patients with UC. Our outcomes showed that; (1) SP supplementation improved serum TAC levels and stool frequency compared to the control group, (2) there were between-group significant differences in changes of health-related quality of life score, and (3) changes in ESR were comparable between groups.

Our observations indicate that SP supplementation may enhance antioxidant capacity and ameliorate oxidation status in patients with UC. Our observations corroborate the antioxidant properties of SP reported in recent studies [56]. Coskun et al. [57] and Abdel-Daim et al. [58] reported that SP intake led to a considerable enhancement of antioxidant potential and consequently reduced lipid peroxidation in rat models with acid-induced colitis. Similarly, Szulinska et al. [35] showed that 2 g/d of SP supplementation for a period of 3 months significantly promoted total antioxidant status in obese participants. Ismail et al. [59] also revealed that 1 g/d of SP administration for 2 months significantly reduced serum content of lipid peroxidation products and improved the antioxidant-related activity of enzymes, such as SOD and glutathione-s-transferase (GST) in patients with chronic obstructive pulmonary disease (COPD). Two unique pigments, the blue C-phycocyanin and yellow-to-red carotenoids are the most critical bioactivities influencing the antioxidant properties of SP [56, 60]. The SP-derived C-phycocyanin can have health-protective properties against oxidative stress harms through scavenging reactive oxygen species (ROS) and decreasing lipid peroxidation in liver microsomes [56, 60, 61]. Moreover, the yellow-to-red carotenoid content of SP acts as an antioxidant by decreasing oxygen-mediated lipid peroxidation and inhibiting the intracellular accumulation of ROS [56, 60, 62]. Accordingly, SP may alleviate UC symptoms by inhibiting oxidative stress and associated complications.

Another important finding from the current work is an improved health-related quality of life score in patients who received the SP supplementation compared to controls. An improved stool frequency score is among the most critical factors in improving the quality of life in patients with UC [63]. Besides pharmaceutical agents, various complementary therapies have been proposed to improve stool frequency and disease activity and increase the quality of life in patients with colitis [19, 64,65,66]. Of current therapies, the modification of the intestine microbiome by probiotics or symbiotics has received significant attention [64, 65, 67, 68]. Studies have documented that combination therapies containing Lactobacillus and Bifidobacterium strains and mesalazine decreased stool frequency and extended remission periods in patients with UC [67, 69]. Also, SP has prebiotic effects and can modulate gut microbiota [30, 70, 71]. In a dose-response model, Hu et al. [70] reported that oral SP supplementation altered the colonic microbial community in healthy mice. Similarly, Neyrinck et al. [30] reported that mice models supplemented with 5% SP had enhanced gut microbiota, especially regarding Roseburia and Lactobacillus strains. Further, extracellular products of SP significantly improve the growth and survival of the Lactobacillus and Bifidobacterium strains [71, 72]. The SP gut microbial modulating properties have been attributed to its high levels of phenolic bioactive, free amino acids, and nitrogenous compounds [71, 73].

Another mechanism by which SP affects intestinal health may be related to regulating adipokines [74,75,76]. In vitro, in vivo, as well as human models have proposed an interconnected and complex role for leptin, ghrelin, and resistin as pivotal mediators of pro-inflammation that may trigger UC [75, 77, 78]. In a mouse model study, Fujimoto et al. [79] reported that SP was associated with significantly lower leptin concentration. Likewise, Heo et al. [80] reported that SP administration attenuated leptin levels and other metabolites in serum. Moreover, Akbarpour et al. [81] showed a significant decrease in serum resistin concentrations following SP administration in patients with type 2 diabetes. This evidence suggests that the adipokine-regulating benefits of SP supplementation may play a role in managing patients with UC.

The SP has antiangiogenesis properties and fosters wound healing and health status in patients with UC [82, 83]. Angiogenesis is required to supply oxygen and nutrients to healing regions and is essential for lesion healing and tissue regeneration. However, angiogenesis attracts more inflammatory cells and cytokines, aggravating pro-inflammation in a vicious circle that exacerbates mucosal injury in patients with UC [84,85,86]. A critical factor in regulating the angiogenesis process in UC is the vascular endothelial growth factor (VEGF), which can be targeted for complementary treatment and ameliorating pathologic angiogenesis [84, 85]. To that end, Mahmoud et al. [82] have revealed SP antiangiogenic effects mediated by modulated VEGF expression in human colorectal carcinomas (HCC) -bearing mice. Similarly, Aldina et al. [87] showed antiangiogenic impacts of SP through decreasing VEGF expression in the cornea inflammation model in rats. However, other studies conducted by Zeinalian et al. [88] and Mehdinezhad et al. [89] demonstrated that SP did not alter serum VEGF in participants with obesity or diabetic rats. Due to the contradictory results in the available literature, further clinical trials are required to elucidate the potential role of angiogenesis and VEGF modulation in the improvement of disease activity and gut health after SP supplementation in patients with UC.

Several studies have suggested that using acute phase inflammatory markers, such as ESR and PTX-3 are non-invasive, safe, and available methods to reflect disease activity in patients with IBD [9, 11, 12, 15]. Our work revealed marginally significant changes in PTX-3 levels and non-significant changes in ESR after 8 weeks of SP administration compared to the control group. The PTX-3 is the longest member of the pentraxins family released mainly from neutrophils in inflamed colon tissue, especially in crypt abscess injuries of patients with UC [14]. The PTX-3-expressing cells and inflamed neutrophils have been shown to elevate proinflammatory reactions in the colon [14, 90]. Our study was conducted on patients with mild or moderate severity of UC who consumed anti-inflammatory medications, such as mesalazine, to attenuate pro-inflammation in the colon tissues [91]. These medications are known to modulate inflammatory reactions and their systemic biomarkers in patients with UC. Therefore, we may not have captured any net anti-inflammatory effect of SP supplementation by conducting a routine inflammatory profile test. Importantly, we are the first study to show the potential beneficial effect of SP supplementation on PTX-3 levels in individuals with UC.

Strengths and limitations

Among our strengths is that this is the first trial to examine the efficacy of SP supplementation in health status among free-living patients with UC. Furthermore, most participants who completed the trial indicated good compliance with their therapy. Additional strengths of this work include a homogeneous cohort with UC and accounting for patients’ physical activity and dietary intake levels during the intervention as critical confounding factors.

Our study had some limitations. We did not perform colonoscopy or tissue biopsy to evaluate the severity of UC disease due to the invasive nature of these procedures, which might have led to higher attrition rates. However, we applied a valid and reliable SCCAI questionnaire as an effective tool to assess disease status. Another limitation is our use of a per-protocol analysis, which is susceptible to confounding biases, making its findings less generalizable to the broader patient population than those obtained from intention-to-treat analysis. We also did not measure specific disease-related biochemical markers, such as C-reactive protein or fecal calprotectin, which would have strengthen our study design as these markers have better correlation with endoscopic activity in UC. Furthermore, this study did not evaluate the dose-dependent efficacy of SP supplementation; therefore, these relationships remain to be elucidated in future work. Additionally, the intervention period in the current trial was likely not long enough to elicit drastic clinical changes. Consequently, longer interventions utilizing SP supplementation in patients with UC are warranted. Other important components are past knowledge and the duration of UC, which may impact the prognosis and management of this condition and potentially alter the study results since patients learn to self-manage their condition over time. Future work should account for any differences in additional confounding parameters, including past knowledge and length of disease between their experimental groups.

Conclusions

The present study examined the effect of SP supplementation on disease activity, health-related quality of life, serum antioxidant status, and PTX-3 status in patients with UC. Our findings indicate that TAC and stool frequency improved after SP supplementation in this population. In addition, SP supplementation did not change disease activity parameters, PTX-3 levels and ESR. Our findings suggest that SP supplementation may be effective as an adjuvant treatment for managing patients with UC. Therefore, larger trials with longer interventions periods are required to draw more precise conclusions.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due but are available from the corresponding author on reasonable request.

References

  1. Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63(3):629–42.

    Article  CAS  PubMed  Google Scholar 

  2. El-Abhar HS, Hammad LN, Gawad HSA. Modulating effect of ginger extract on rats with ulcerative colitis. J Ethnopharmacol. 2008;118(3):367–72.

    Article  CAS  PubMed  Google Scholar 

  3. Gophna U, et al. Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis. J Clin Microbiol. 2006;44(11):4136–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17(3):831–48.

    Article  PubMed  Google Scholar 

  5. Hanauer SB. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2004;1(1):26–31.

    Article  PubMed  Google Scholar 

  6. Yangyang RY, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. In: Seminars in pediatric surgery. Elsevier; 2017.

    Google Scholar 

  7. Ishihara S, et al. Irritable bowel syndrome-like symptoms in ulcerative colitis patients in clinical remission: association with residual colonic inflammation. Digestion. 2019;99(1):46–51.

    Article  PubMed  Google Scholar 

  8. Chaubal A, et al. Anemia in patients with ulcerative colitis in remission: a study from western India. Indian J Gastroenterol. 2017;36(5):361–5.

    Article  PubMed  Google Scholar 

  9. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7(4):460–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cioffi M, et al. Laboratory markers in ulcerative colitis: current insights and future advances. World J Gastrointest Pathophysiol. 2015;6(1):13.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wu Q, et al. Pentraxin 3: a promising therapeutic target for autoimmune diseases. Autoimmun Rev. 2020;19(12):102584.

    Article  CAS  PubMed  Google Scholar 

  12. Kalyon S, Gökden Y, Oyman F. A new biological marker in inflammatory bowel disease: Pentraxin 3. J Surg Med. 2020;4(10):875–8.

    Article  Google Scholar 

  13. Ishida N, et al. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Sci Rep. 2021;11(1):1–8.

    Article  MathSciNet  Google Scholar 

  14. Savchenko AS, et al. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol Int. 2011;61(5):290–7.

    Article  CAS  PubMed  Google Scholar 

  15. Kato S, et al. Increased expression of long pentraxin PTX3 in inflammatory bowel diseases. Dig Dis Sci. 2008;53(7):1910–6.

    Article  CAS  PubMed  Google Scholar 

  16. Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(6):1280-1290.e1.

    Article  CAS  PubMed  Google Scholar 

  17. Lamb CA, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–106.

    Article  PubMed  Google Scholar 

  18. Naganuma M, et al. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol. 2016;9(6):329–36.

    Article  PubMed  Google Scholar 

  19. Nikkhah-Bodaghi M, et al. The effects of Nigella sativa on quality of life, disease activity index, and some of inflammatory and oxidative stress factors in patients with ulcerative colitis. Phytother Res. 2019;33(4):1027–32.

    Article  CAS  PubMed  Google Scholar 

  20. Rastegarpanah M, et al. A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis. Chin J Integr Med. 2015;21(12):902–6.

    Article  CAS  PubMed  Google Scholar 

  21. Nikkhah-Bodaghi M, et al. Zingiber officinale and oxidative stress in patients with ulcerative colitis: a randomized, placebo-controlled, clinical trial. Complement Ther Med. 2019;43:1–6.

    Article  PubMed  Google Scholar 

  22. Sadeghi N, et al. The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytother Res. 2020;34(5):1123–33.

    Article  CAS  PubMed  Google Scholar 

  23. Samsamikor M, et al. Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res. 2016;47(4):304–9.

    Article  CAS  PubMed  Google Scholar 

  24. Amiri M, et al. Efficacy and safety of a standardized extract from Achillea wilhelmsii C. Koch in patients with ulcerative colitis: a randomized double blind placebo-controlled clinical trial. Complement Ther Med. 2019;45:262–8.

    Article  PubMed  Google Scholar 

  25. Kulshreshtha A, et al. Spirulina in health care management. Curr Pharm Biotechnol. 2008;9(5):400–5.

    Article  CAS  PubMed  Google Scholar 

  26. Yousefi R, Saidpour A, Mottaghi A. The effects of Spirulina supplementation on metabolic syndrome components, its liver manifestation and related inflammatory markers: a systematic review. Complement Ther Med. 2018;42.

  27. Wu Q, et al. The antioxidant, immunomodulatory, and anti-inflammatory activities of Spirulina: an overview. Arch Toxicol. 2016;90:1817–40.

    Article  CAS  PubMed  Google Scholar 

  28. Mazokopakis EE, et al. The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric. 2014;94(3):432–7.

    Article  CAS  PubMed  Google Scholar 

  29. Suliburska J, et al. Effect of Spirulina maxima supplementation on calcium, magnesium, iron, and zinc status in obese patients with treated hypertension. Biol Trace Elem Res. 2016;173(1):1–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Neyrinck AM, et al. Spirulina protects against hepatic inflammation in aging: an effect related to the modulation of the gut microbiota? Nutrients. 2017;9(6):633.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Bobescu E, et al. Are there any beneficial effects of Spirulina supplementation for metabolic syndrome components in postmenopausal women? Mar Drugs. 2020;18(12):651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Guazelli CF, et al. Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis. Chem Biol Interact. 2021;333:109315.

    Article  CAS  PubMed  Google Scholar 

  33. Zuo K, et al. Purification and antioxidant and anti-inflammatory activity of extracellular polysaccharopeptide from sanghuang mushroom, Sanghuangporus lonicericola. J Sci Food Agric. 2021;101(3):1009–20.

    Article  CAS  PubMed  Google Scholar 

  34. Tzachor A, et al. Photosynthetically controlled Spirulina, but not solar Spirulina, inhibits TNF-α secretion: potential implications for COVID-19-related cytokine storm therapy. Mar Biotechnol. 2021;23(1):149–55.

    Article  CAS  Google Scholar 

  35. Szulinska M, et al. Spirulina maxima improves insulin sensitivity, lipid profile, and total antioxidant status in obese patients with well-treated hypertension: a randomized double-blind placebo-controlled study. Eur Rev Med Pharmacol Sci. 2017;21(10):2473–81.

    CAS  PubMed  Google Scholar 

  36. Kordi MR, Attarzade Hosseini SR, Davaloo T. Aerobic exercises and supplement Spirulina reduce inflammation in diabetic men. J Jahrom Univer Med Sci. 2018;16(4):10–8.

    Google Scholar 

  37. Morsy MA, et al. Protective effect of Spirulina platensis extract against dextran-sulfate-sodium-induced ulcerative colitis in rats. Nutrients. 2019;11(10):2309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. El-Boghdady NA, Kamel MA, El-Shamy RM. Omeprazole and Spirulina platensis ameliorate Steatohepatitis in experimental nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2020;18(9):426–34.

    Article  CAS  PubMed  Google Scholar 

  39. Windari HAS, et al. Antioxidant activity of Spirulina platensis and sea cucumber Stichopus hermanii in Streptozotocin-induced diabetic rats. Trop Life Sci Res. 2019;30(2).

  40. Gómez-Téllez A, et al. Effects of a low-dose Spirulina/turmeric supplement on Cardiometabolic and antioxidant serum markers of patients with abdominal obesity. Front Nutr. 2020;7.

  41. Nasirian F, et al. Effects of Spirulina platensis microalgae on antioxidant and anti-inflammatory factors in diabetic rats. Diabet Metab Syndr Obes: Targets Ther. 2018;11:375.

    Article  CAS  Google Scholar 

  42. Martínez-Sámano J, et al. Spirulina maxima decreases endothelial damage and oxidative stress indicators in patients with systemic arterial hypertension: results from exploratory controlled clinical trial. Mar Drugs. 2018;16(12):496.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Jowett S, et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol. 2003;38(2):164–71.

    Article  CAS  PubMed  Google Scholar 

  44. Zeinalian R, et al. The effects of Spirulina platensis on anthropometric indices, appetite, lipid profile and serum vascular endothelial growth factor (VEGF) in obese individuals: a randomized double blinded placebo controlled trial. BMC Complement Altern Med. 2017;17(1):1–8.

    Article  MathSciNet  Google Scholar 

  45. Mazokopakis EE, et al. The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study. Ann Gastroenterol: Q Publ Hellenic Soc Gastroenterol. 2014;27(4):387.

    Google Scholar 

  46. Rezaei N, et al. The protective effects of honey and spirulina platensis on acetic acid-induced ulcerative colitis in rats. Iran Red Crescent Med J. 2018;20(4):8.

    Article  Google Scholar 

  47. Dai Y-C, et al. Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: a randomized controlled trial. Medicine. 2017;96(16):e6651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Naganuma M, et al. Efficacy of indigo Naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis. Gastroenterology. 2018;154(4):935–47.

    Article  PubMed  Google Scholar 

  49. Committee, I.R., Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ)-short and long forms. http://www.ipaq.ki.se/scoring.pdf, 2005.

  50. Walmsley R, et al. A simple clinical colitis activity index. Gut. 1998;43(1):29–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Jowett SL, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96(10):2921–8.

    Article  CAS  PubMed  Google Scholar 

  52. Bijari B, Soltani B. Validation of the Persian version of inflammatory bowel disease questionnaire in patients who referred to clinics and hospitals of Birjand university of medical sciences, Iran. Ann Colorectal Res. 2017;5(1-2).

  53. Faul F, et al. G* power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.

    Article  PubMed  Google Scholar 

  54. Langmead L, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004;19(7):739–47.

    Article  CAS  PubMed  Google Scholar 

  55. Kamali M, et al. Efficacy of the Punica granatum peels aqueous extract for symptom management in ulcerative colitis patients. A randomized, placebo-controlled, clinical trial. Complement Ther Clin Pract. 2015;21(3):141–6.

    Article  PubMed  Google Scholar 

  56. Park WS, et al. Two classes of pigments, carotenoids and c-phycocyanin, in spirulina powder and their antioxidant activities. Molecules. 2018;23(8):2065.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Coskun ZK, et al. The study of biochemical and histopathological effects of spirulina in rats with TNBS-induced colitis. Bratisl Lek Listy. 2011;112(5):235–43.

    CAS  PubMed  Google Scholar 

  58. Abdel-Daim MM, et al. Anti-inflammatory and immunomodulatory effects of Spirulina platensis in comparison to Dunaliella salina in acetic acid-induced rat experimental colitis. Immunopharmacol Immunotoxicol. 2015;37(2):126–39.

    Article  CAS  PubMed  Google Scholar 

  59. Ismail M, et al. Effect of spirulina intervention on oxidative stress, antioxidant status, and lipid profile in chronic obstructive pulmonary disease patients. Biomed Res Int. 2015;2015.

  60. Yousefi R, Saidpour A, Mottaghi A. The effects of Spirulina supplementation on metabolic syndrome components, its liver manifestation and related inflammatory markers: a systematic review. Complement Ther Med. 2019;42:137–44.

    Article  PubMed  Google Scholar 

  61. Grover P, et al. C-Phycocyanin-a novel protein from Spirulina platensis- in vivo toxicity, antioxidant and immunomodulatory studies. Saudi J Biol Sci. 2021;28(3):1853–9.

    Article  CAS  PubMed  Google Scholar 

  62. Schafer FQ, et al. Comparing β-carotene, vitamin E and nitric oxide as membrane antioxidants. Biol Chem. 2002;383(3–4):671–81.

    CAS  PubMed  Google Scholar 

  63. Rasmussen B, et al. Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. Scand J Gastroenterol. 2020;55(6):656–63.

    Article  PubMed  Google Scholar 

  64. van der Waal MB, et al. Probiotics for improving quality of life in ulcerative colitis: exploring the patient perspective. PharmaNutrition. 2019;7:100139.

    Article  Google Scholar 

  65. Amiriani T, et al. Effect of Lactocare® synbiotic on disease severity in ulcerative colitis: a randomized placebo-controlled double-blind clinical trial. Middle East J Dig Dis. 2020;12(1):27.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Shirazi KM, et al. Effect of N-acetylcysteine on remission maintenance in patients with ulcerative colitis: a randomized, double-blind controlled clinical trial. Clin Res Hepatol Gastroenterol. 2020;45.

  67. Dhillon P, Singh K. Therapeutic applications of probiotics in ulcerative colitis: an updated review. PharmaNutrition. 2020;13:100194.

    Article  Google Scholar 

  68. Dang X, et al. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL# 3 for active ulcerative colitis: a systematic review and meta-analysis. PLoS One. 2020;15(3):e0228846.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Astó E, et al. The efficacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: a systematic review and meta-analysis. Nutrients. 2019;11(2):293.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Hu J, et al. Dose effects of orally administered Spirulina suspension on colonic microbiota in healthy mice. Front Cell Infect Microbiol. 2019;9:243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Finamore A, et al. Antioxidant, immunomodulating, and microbial-modulating activities of the sustainable and ecofriendly spirulina. Oxidative Med Cell Longev. 2017;2017.

  72. Parada JL, et al. Lactic acid bacteria growth promoters from Spirulina platensis. Int J Food Microbiol. 1998;45(3):225–8.

    Article  CAS  PubMed  Google Scholar 

  73. Beheshtipour H, et al. Supplementation of Spirulina platensis and Chlorella vulgaris algae into probiotic fermented milks. Compr Rev Food Sci Food Saf. 2013;12(2):144–54.

    Article  CAS  Google Scholar 

  74. Kaka R, et al. The effect of nonlinear resistance training with supplementation of Spirulina on serum leptin and ghrelin in obese women. J Appl Health Stud Sport Physiol. 2019;6(1):69–77.

    Google Scholar 

  75. Karmiris K, Koutroubakis IE, Kouroumalis EA. Leptin, adiponectin, resistin, and ghrelin–implications for inflammatory bowel disease. Mol Nutr Food Res. 2008;52(8):855–66.

    Article  CAS  PubMed  Google Scholar 

  76. Ghomraoui FA, et al. Plasma ghrelin and leptin in patients with inflammatory bowel disease and its association with nutritional status. Saudi J Gastroenterol: Off J Saudi Gastroenterol Assoc. 2017;23(3):199.

    Article  Google Scholar 

  77. Jung JY, et al. Circulating ghrelin levels and obestatin/ghrelin ratio as a marker of activity in ulcerative colitis. Intest Res. 2015;13(1):68–73.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Biesiada G, et al. Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea. J Physiol Pharmacol. 2012;63(5):471–81.

    CAS  PubMed  Google Scholar 

  79. Fujimoto M, et al. Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Dig Liver Dis. 2012;44(9):767–74.

    Article  CAS  PubMed  Google Scholar 

  80. Heo M-G, Choung S-Y. Anti-obesity effects of Spirulina maxima in high fat diet induced obese rats via the activation of AMPK pathway and SIRT1. Food Funct. 2018;9(9):4906–15.

    Article  CAS  PubMed  Google Scholar 

  81. Akbarpour M, Samari Z. The effect of aerobic training and Spirulina supplementation on Resistin and C-reactive protein in women with type 2 diabetes with overweight. KAUMS J (FEYZ). 2020;24(5):576–84.

    Google Scholar 

  82. Mahmoud YI, et al. Spirulina inhibits hepatocellular carcinoma through activating p53 and apoptosis and suppressing oxidative stress and angiogenesis. Life Sci. 2021;265:118827.

    Article  CAS  PubMed  Google Scholar 

  83. Elbialy ZI, et al. Healing potential of Spirulina platensis for skin wounds by modulating bFGF, VEGF, TGF-ß1 and α-SMA genes expression targeting angiogenesis and scar tissue formation in the rat model. Biomed Pharmacother. 2021;137:111349.

    Article  CAS  PubMed  Google Scholar 

  84. Mateescu RB, et al. Vascular endothelial growth factor-key mediator of angiogenesis and promising therapeutical target in ulcerative colitis. Romanian J Morphol Embryol. 2017;58(4):1339–45.

    Google Scholar 

  85. Aksoy EK, et al. Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study. Sao Paulo Med J. 2018;136(6):543–50.

    Article  PubMed  Google Scholar 

  86. Sandor Z, et al. Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun. 2006;350(1):147–50.

    Article  CAS  PubMed  Google Scholar 

  87. Aldina R, Haryati SW. Effect of Spirulina platensis extract on vascular endothelial growth factor (VEGF) expression in corneal inflammation in rat (Rattus novergicus) strain wistar. EurAsian J BioSci. 2019;13(2):823–9.

    CAS  Google Scholar 

  88. Zeinalian R, et al. The effects of Spirulina platensis on anthropometric indices, appetite, lipid profile and serum vascular endothelial growth factor (VEGF) in obese individuals: a randomized double blinded placebo controlled trial. BMC Complement Altern Med. 2017;17(1):225.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Mehdinezhad N, et al. Effect of spirulina and chlorella alone and combined on the healing process of diabetic wounds: an experimental model of diabetic rats. J Diab Metab Disord. 2021;20.

  90. Ercan G, Yigitturk G, Erbas O. Therapeutic effect of adenosine on experimentally induced acute ulcerative colitis model in rats. Acta Cir Bras. 2019;34(12).

  91. Rubin DT, et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial. J Crohn’s Colitis. 2017;11(7):785–91.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank all participants who kindly contributed to the study.

Funding

The current work is a part of a PhD thesis supported by a grant (No.398533) from the Vice-Chancellor for Research at Isfahan University of Medical Sciences in Iran.

Author information

Authors and Affiliations

  1. Department of Nutrition and Food Sciences, Research Center for Evidence-Based Health Management, Maragheh University of Medical Sciences, Maragheh, Iran

    Sajjad Moradi

  2. Department of Exercise Physiology, University of Isfahan, Isfahan, 8174673441, Iran

    Reza Bagheri

  3. General Practitioner, Kermanshah University of Medical Sciences (KUMS), Kermanshah, Iran

    Parsa Amirian & Mahsa Zarpoosh

  4. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, 1417613151, Iran

    Neda Cheraghloo

  5. Department of Health and Human Performance, Marymount University, Arlington, VA, USA

    Alexei Wong

  6. Department of Internal Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Mehdi Zobeiri

  7. Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

    Mohammad Hassan Entezari

Authors
  1. Sajjad Moradi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reza Bagheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Parsa Amirian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mahsa Zarpoosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Neda Cheraghloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexei Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mehdi Zobeiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mohammad Hassan Entezari
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

“SM, MZ and ME designed this study. SM, MZ and ME contributed to the conduct of the trial. SM and NC-h performed the statistical analysis and interpreted the results. SM wrote the initial manuscript. AW and RB critically revised the manuscript and contributed to the subsequent drafts of the manuscript. PA and Mahsa Zarpoosh were contributes to revise. All authors approved the final version of the manuscript”.

Corresponding author

Correspondence to Mohammad Hassan Entezari.

Ethics declarations

Ethics approval and consent to participate

All study protocols were carried out according to the Declaration of Helsinki. All patients provided written informed consent before participation in the trial. The study protocol was approved by the ethical committee at the Isfahan University of Medical Sciences (code: IR.MUI.RESEARCH.REC.1398.436, approval date 23/10/2019) and registered online at http://www.IRCT.ir (code: IRCT20191204045612N1, register date 05/04/2021).

Consent for publication

All authors have agreed to submit the manuscript to BMC Complementary Medicine and Therapies.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moradi, S., Bagheri, R., Amirian, P. et al. Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial. BMC Complement Med Ther 24, 109 (2024). https://doi.org/10.1186/s12906-024-04400-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-024-04400-w

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us